Literature DB >> 20222297

Drug-induced QT prolongation and sudden death.

Marc E Del Rosario1, Richard Weachter, Greg C Flaker.   

Abstract

Prolongation of the QT interval can predispose to a potentially fatal polymorphic ventricular tachycardia called torsades de pointes (TdP). Although usually self-limited, TdP may degenerate into ventricular fibrillation and cause sudden death. Some medications that cause QT prolongation and possible TdP are commonly used in general practice. This paper presents a case of sudden death that is likely from drug-induced TdP. It reviews the mechanisms, risk factors, offending agents, and management of drug-induced torsades de pointes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20222297      PMCID: PMC6192813     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  24 in total

1.  Drug-induced torsade de pointes.

Authors:  R G Trohman; J Sahu
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

Review 2.  Drug induced QT prolongation and torsades de pointes.

Authors:  Yee Guan Yap; A John Camm
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

3.  QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

Authors:  A SELZER; H W WRAY
Journal:  Circulation       Date:  1964-07       Impact factor: 29.690

4.  Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia.

Authors:  J Morganroth; F V Brozovich; J T McDonald; R A Jacobs
Journal:  Am J Cardiol       Date:  1991-04-01       Impact factor: 2.778

Review 5.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.

Authors:  D M Roden; R Lazzara; M Rosen; P J Schwartz; J Towbin; G M Vincent
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

6.  Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.

Authors:  Ping Yang; Hideaki Kanki; Benoit Drolet; Tao Yang; Jian Wei; Prakash C Viswanathan; Stefan H Hohnloser; Wataru Shimizu; Peter J Schwartz; Marshall Stanton; Katherine T Murray; Kris Norris; Alfred L George; Dan M Roden
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

7.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.

Authors:  M L De Bruin; M Pettersson; R H B Meyboom; A W Hoes; H G M Leufkens
Journal:  Eur Heart J       Date:  2005-01-06       Impact factor: 29.983

8.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 9.  Antiarrhythmic drugs and torsade de pointes.

Authors:  R Lazzara
Journal:  Eur Heart J       Date:  1993-11       Impact factor: 29.983

Review 10.  What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers.

Authors:  Sergio L Pinski; Luis E Eguía; Richard G Trohman
Journal:  Pacing Clin Electrophysiol       Date:  2002-11       Impact factor: 1.976

View more
  9 in total

Review 1.  Induced pluripotent stem cells as a disease modeling and drug screening platform.

Authors:  Antje D Ebert; Ping Liang; Joseph C Wu
Journal:  J Cardiovasc Pharmacol       Date:  2012-10       Impact factor: 3.105

Review 2.  Arrhythmia risk in liver cirrhosis.

Authors:  Ioana Mozos
Journal:  World J Hepatol       Date:  2015-04-08

Review 3.  Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases.

Authors:  Young Wook Chun; Matthew D Durbin; Charles C Hong
Journal:  Curr Cardiol Rep       Date:  2018-04-17       Impact factor: 2.931

Review 4.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

5.  Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Ericka L Breden Crouse; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-10

Review 6.  Cellular model systems to study cardiovascular injury from chemotherapy.

Authors:  Hananeh Fonoudi; Paul W Burridge
Journal:  J Thromb Thrombolysis       Date:  2020-10-13       Impact factor: 5.221

Review 7.  Cardiovascular considerations in antidepressant therapy: an evidence-based review.

Authors:  Habibeh Yekehtaz; Mehdi Farokhnia; Shahin Akhondzadeh
Journal:  J Tehran Heart Cent       Date:  2013-10-28

8.  Possible Azithromycin-Induced Life-Threatening Arrhythmia Requiring Extracorporeal Membrane Oxygenation Support: A Case Report.

Authors:  Abdulrazaq S Al-Jazairi; Haifa S Alotaibi
Journal:  Am J Case Rep       Date:  2020-11-12

Review 9.  Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart.

Authors:  Revanth Kalluru; Sai Gadde; Rahul Chikatimalla; Thejaswi Dasaradhan; Jancy Koneti; Swathi Priya Cherukuri
Journal:  Cureus       Date:  2022-08-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.